- Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed
- Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose
Cohort 8
- The cohort (2.88 mg/kg) is now fully enrolled with 20 patients
Recommended phase 2 dose expected by early next year